Font Size: a A A

A Clinical Study Of Advanced Lung Cancer With The Qing-jin-de-sheng-pian And Mechanism Analysis

Posted on:2007-07-23Degree:DoctorType:Dissertation
Country:ChinaCandidate:H J WuFull Text:PDF
GTID:1104360185453241Subject:Traditional Chinese Medicine
Abstract/Summary:PDF Full Text Request
Objective: The incidence and the mortality of lung cancer increased continuously in the world. In china, plenty of patients with advanced lung cancer, and patients of metastasis or recrudescence that is after operation, chemotherapy and radiotherapy is treated by Traditional Chinese Medicine (TCM). Through several decades' clinical and experimental study, TCM can improve the life quality, delay the cancer development, recrudescence and metastasis, and prolong survival time. According to the pathogenesis, lung cancer were determined form four pattern: lung depression with phlegm stasis, spleen deficiency with phlegm damp, yin deficiency with phlegm heat, qi and yin deficiency and meeting phlegm stasis toxin. With the change of illness State, the types change too. The bases of lung cancer and pathogenesis after the remedy by Western Medicine are qi and yin deficiency, so we put forward that "supplementing qi and nourishing yin and resolve phlegm and remove toxin" is the therapeutic principle on advanced lung cancer and Qing-jin-de-sheng-pian is the representative prescription. This paper will approach the effect and mechanism of Qing-jin-de-sheng-pian. Methods: The advanced lung cancer patients of qi and yin deficiency and meeting phlegm stasis toxin were included in this single random prospective control study. They were divided two groups, treatment group and control group. Patients were observed tumor, Karnofsky performance score and body weight in prior and post treatment, and clinical signs score, CEA and ESR monthly. In the experimental study of gene chip, we observed the influence of medicinal serum of Qing-jin-de-sheng-pian in gene expression profile of LAC. Results: In clinical' study: â‘ Both efficiency of two groups are 0%. Thestability of treatment group 76.67% was higher than control group 71.43 %. There was no obvious difference between groups (P>0. 05). ?Treatment group was obvious difference in clinical signs score after 30, 60, 90 days of treatment (P<0. 05);and control group was obvious difference in clinical signs score after 60, 90 days of treatment (P<0.05). There was obvious difference between groups after 60, 90 days of treatment (P<0. 05). ?Both groups were obvious difference in CEA after 90 days of treatment (P<0. 05);and there was no obvious difference in CEA between groups after treatment (P>0.05). Both groups were obvious difference in ESR after 60, 90 days of treatment (P<0. 05);and there was no obvious difference in ESR between groups after treatment (P>0. 05). (4)There was obvious difference between groups in body weight after treatment (P<0. 05);there was no obvious difference in body weight each group after treatment (P>0.05). ?There was no obvious difference in Karnofsky performance score between groups after treatment (P>0. 05);and there was obvious difference in Karnofsky performance score each group after treatment (P>0. 05). ?In this research, there was not adverse events. In control group two patients appeared Nausea and vomiting, and appealed to go out. In the experimental study, the results showed that most gene expression which were significantly different between the experiment group and the control group were similar with that between the experimental group and the blank group, which suggested that many genes of that were directly associated with effect of the drug. Compared with control group and blank group, experimental group genes expressed differently, including intracellular signal transduction pathway (ARF1, SEMA3B, plOO, CTSF, GLE1L, MYOG, NRBP, PPP3CC, FSTL3, IER3, CYBA, etc.), cellular metabolism, receptor and immunity(HLA-G, NMBR, DIPA, EN01, ENO3, LY64, etc.) , DNA replication and regeneration (H1F0, HMG20B, HSGP25L2G, etc. ) , Cytoskeleton Protein (KRT8, etc. ) and ionic channel proteins1 (KCNN4, SLC21A12, etc. ) .Conclusions: In a word, it was showed that the using of Qing-jin-de-sheng-pian can stabilize tumor, clinical signs score and Karnofsky performance score, and bring low CEA and ESR, and gain body weight. Without adverse reaction, the therapeutic efficacy of Qing-jin-de-sheng-pian increased with time expands, so we can said, the using of Qing-jin-de-sheng-pian on advanced lung cancer with qi and yin deficiency and meeting phlegm stasis toxin were safetyand availability. The influence of medicinal serum of Qing-jin-de-sheng-pian in gene expression profile of LAC was extensive.
Keywords/Search Tags:Advanced non-small cell lung cancer, Qing-jin-de-sheng-pian, boosting qi and supplement yin, removing phlegm and resolving toxin, gene chip
PDF Full Text Request
Related items